This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción CEPS
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de CTI BioPharma Corp.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.23 |
| 52 Week High | US$8.44 |
| 52 Week Low | US$3.70 |
| Beta | 0.83 |
| 1 Month Change | -0.19% |
| 3 Month Change | 109.73% |
| 1 Year Change | 59.14% |
| 3 Year Change | 714.44% |
| 5 Year Change | 81.37% |
| Change since IPO | -69.84% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| CEPS | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0.9% | 1.8% | -0.3% |
| 1Y | 59.1% | -19.9% | 2.8% |
Rentabilidad vs. Industria: CEPS exceeded the German Biotechs industry which returned -8.9% over the past year.
Rentabilidad vs. Mercado: CEPS exceeded the German Market which returned 1.4% over the past year.
Volatilidad de los precios
| CEPS volatility | |
|---|---|
| CEPS Average Weekly Movement | 25.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: CEPS's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: CEPS's weekly volatility has increased from 15% to 25% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1991 | 128 | Adam Craig | www.ctibiopharma.com |
Resumen de fundamentos de CTI BioPharma Corp.
| Estadísticas fundamentales de CEPS | |
|---|---|
| Capitalización bursátil | €1.09b |
| Beneficios(TTM) | -€63.16m |
| Ingresos (TTM) | €69.12m |
15.8x
Ratio precio-ventas (PS)-17.3x
Ratio precio-beneficio (PE)¿Está CEPS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CEPS | |
|---|---|
| Ingresos | US$75.77m |
| Coste de los ingresos | US$4.46m |
| Beneficio bruto | US$71.31m |
| Otros gastos | US$140.55m |
| Beneficios | -US$69.24m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.53 |
| Margen bruto | 94.11% |
| Margen de beneficio neto | -91.38% |
| Ratio deuda/patrimonio | -459.4% |
¿Cómo se ha desempeñado CEPS a largo plazo?
Ver rendimiento histórico y comparativa